You're standing at the pharmacy counter. The number on the insulin box is enough to make you flinch, even though the vial itself costs the manufacturer only a few dollars to produce. Insurance was supposed to fix this. But the figure on your receipt didn't come from nowhere, and it didn't come purely from one greedy manufacturer either — it passed through a layer of middlemen most patients don't even know exists.
That layer is called a Pharmacy Benefit Manager, or PBM. On paper, its job is to negotiate with drug manufacturers on behalf of insurers and employers to bring prices down. In practice, three companies that process the bulk of prescriptions in the country have wedged themselves between you and your medication so thoroughly that they now profit from the fact that you're sick — regardless of whether the drug got cheaper or more expensive.
Three companies run almost the whole market
The PBM market in the US stopped being a market in any normal sense a long time ago — it's an oligopoly of three. CVS Caremark, Express Scripts (part of Cigna, under the Evernorth brand), and OptumRx (owned by UnitedHealth Group) together handle, by various estimates, on the order of 80 percent of all prescription claims processed through insurance plans nationwide. When three companies decide which drug makes your plan's formulary and which doesn't, they're effectively writing the menu the whole country orders from.
Formally, a PBM is neither a manufacturer nor an insurer. It's a middleman, administrative plumbing. But scale turns plumbing into leverage: if you make a drug and you haven't struck a deal with one of these three, tens of millions of insured patients simply cannot get your product through their coverage.
The rebate deal nobody explains to you
The core of the PBM business is negotiating so-called rebates — payments a drug manufacturer makes to the middleman in exchange for a spot on the formulary. The idea on paper is reasonable: competition for that spot should push prices down. In practice, there's a built-in perversity to it.
The rebate is calculated as a percentage of the drug's list price — the sticker price, which is often inflated to begin with. The higher the list price, the bigger the rebate in absolute dollars the PBM can collect. That gives the manufacturer an incentive not to lower the price but to raise it and offer the middleman a bigger slice — just to keep the formulary spot. The PBM makes more money when the drug costs more, not less. That is a large part of why insulin, asthma inhalers, and diabetes medication have stayed several times more expensive in the US than in most other wealthy countries for years running.
And at the counter, the patient almost always pays a share of that inflated list price — not the net price after the rebate. The discount the whole arrangement was supposedly built around never reaches the register. It stays further up the chain.
Spread pricing: a second margin
The second revenue stream runs quieter and gets almost no public attention. It's called spread pricing. The PBM bills the insurance plan or the employer one amount for a dispensed drug and reimburses the pharmacy a smaller amount. The difference — the spread — stays with the middleman.
Neither the pharmacy, nor the patient, nor often even the employer footing the bill for its employees' coverage sees the full chain of numbers. PBM contracts have historically been shielded by confidentiality clauses so tight that even large corporate purchasers of insurance can't find out exactly how much the middleman made off their employees' health. The Federal Trade Commission, in an interim report from its 2024 investigation, found that the three largest PBMs marked up certain specialty generic drugs by margins measured in the thousands of percent above acquisition cost.
One owner sitting on every side of the table
This is where the mechanism tightens the most. Each of the three biggest PBMs is no longer an independent broker — it belongs to the same corporation that owns the insurer and, increasingly, the pharmacy chain. CVS Caremark sits inside CVS Health, which also owns the insurer Aetna and the CVS retail pharmacy chain. Express Scripts sits inside Cigna. OptumRx belongs to UnitedHealth Group, which also owns the country's largest insurer, UnitedHealthcare, and a network of specialty pharmacies under the Optum brand.
Our record: this is a textbook Shadow Isis pattern — control dressed up as care. The vertically integrated giant tells you: "we're negotiating on your behalf, we're protecting your wallet from greedy drugmakers." In reality, one corporate hand is negotiating with itself — the insurer decides what's covered, the PBM decides who gets paid, and the pharmacy under the same parent gets the patient routed straight to its own counter. Three nodes of one network invoice each other and call it competition.
The independent pharmacy on the corner dies first
This structure has a side effect that's easier to see on the street than in a filing. Independent pharmacies — the ones where the pharmacist knows your name — have complained for years that PBMs reimburse them below what they paid wholesale for the drug. Operating at a loss on every prescription isn't sustainable for long, and across the country, especially in rural areas and low-income urban neighborhoods, independent pharmacies have been closing, leaving behind what the industry and health-policy reporting call pharmacy deserts — stretches where the nearest place to fill a prescription is tens of miles away.
For a long time, PBM contracts also contained so-called gag clauses — provisions that literally barred a pharmacist from telling a patient that paying cash would be cheaper than their own insurance copay. Some of these clauses have since been banned by federal and state law, but the fact that such a clause existed at all in mainstream contracts is a precise snapshot of whose interest the system defaulted to protecting.
Where things stand now
Transparency in this layer has stopped being a purely theoretical demand. The Federal Trade Commission has an active investigation into the largest PBMs, several states have filed their own lawsuits, and Congress has spent years debating bills that would decouple the middleman's compensation from a drug's list price and require disclosure of the actual size of rebates and spreads. None of those bills has become federal law yet — the interests built around the current arrangement are organized and lobby just as hard as the manufacturers PBMs are supposedly there to discipline.
A layer that was supposed to protect patients from inflated prices has instead become the most profitable part of the chain, one that earns more precisely when the price stays high, not when it falls. Until this arrangement is broken from the outside — by regulation, by lawsuits, by employers and patients organizing to demand the actual numbers — it will not break on its own: none of the three nodes in this network has any incentive to loosen its grip voluntarily. Understanding how the middleman between you and your medication actually works is not idle curiosity. It's the first step toward asking your employer, your plan, and your state not "why is this so expensive," but "who exactly is profiting here, and on what" — and demanding an answer in numbers, not in language about caring for your health.